World Companion Diagnostics Summit (CDx Summit)

Venue: Boston

Location: Boston, Massachusetts, United States

Event Date/Time: Nov 28, 2011 End Date/Time: Dec 10, 2011
Report as Spam


World Companion Diagnostics Summit returns to Boston

The must-attend forum for drug and diagnostic developers is back. The World Companion Diagnostics Summit has been designed by leading biomarker and companion diagnostics specialists at Roche, Novartis, Johnson & Johnson, GSK, Merck, AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Pfizer and many more to assist you in turning biomarker research into successful patient stratification and to deliver better, safer drugs to market with drug-diagnostic co-development.

With all the fascinating feedback we’ve heard from you over the last few months, we’re putting together an agenda this year that’s packed with fresh, new insights and that addresses the most up-to-date issues and challenges in drug-diagnostic co-development.

So what’s on the agenda?

Key topics that have emerged this year that people really want to hear about are:

• The different CDx strategies companies are taking, both in large pharma and smaller drug developing companies: How are they going about trying to stratify patient populations? E.g. In-house development vs. outsourcing? LDT vs. IVD? Prospective vs. retrospective biomarker development?
• Who has run or is looking to prospectively run their clinical trial based on their biomarker? Who has retrospectively identified a biomarker that they are now integrating into clinical trials for patient stratification, including post-market approval?
• What does the regulatory and reimbursement landscape of CDx development look like?
• How do we ensure a CDx product gets on to the market and achieves return on investment?
• How do we translate biomarkers from the laboratory to the clinic and achieveassay validation?
• What are the partnering options and opportunities for CDx? How do webalance the risk and reward of CDx development by structuring partnership deals for mutual benefit?
• When is the best time to partner?
• What are the latest tools and technologies that could have an impact on patient stratification? E.g. next-generation sequencing, point of care diagnostics, multiplex assays based on biosignatures etc.
• How do we ensure access to clinical samples needed for biomarker identification and CDx development?
These topics will form the core of this year’s agenda.

To register simply:
Call: +44 20 3141 8700

Please quote the booking code: LIST when registering to secure your place at the meeting.


Charter House, 13-15 Carteret Street
United States